국가: 미국
언어: 영어
출처: NLM (National Library of Medicine)
HYDROCODONE BITARTRATE (UNII: NO70W886KK) (HYDROCODONE - UNII:6YKS4Y3WQ7), ACETAMINOPHEN (UNII: 362O9ITL9D) (ACETAMINOPHEN - UNII:362O9ITL9D)
PAI Holdings, LLC
HYDROCODONE BITARTRATE
HYDROCODONE BITARTRATE 7.5 mg in 15 mL
ORAL
PRESCRIPTION DRUG
Hydrocodone Bitartrate and Acetaminophen Oral Solution is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see WARNINGS ], reserve Hydrocodone Bitartrate and Acetaminophen Oral Solution for use in patients for whom alternative treatment options (e.g., non-opioid analgesics): - have not been tolerated, or are not expected to be tolerated - have not provided adequate analgesia, or are not expected to provide adequate analgesia Hydrocodone Bitartrate and Acetaminophen Oral Solution is contraindicated in patients with: • Significant respiratory depression [see WARNINGS ] • Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see WARNINGS] • Known or suspected gastrointestinal obstruc
Hydrocodone Bitartrate and Acetaminophen Oral Solution is a yellow-colored, fruit flavored liquid containing 7.5 mg hydrocodone bitartrate and 325 mg acetaminophen per 15 mL, with 6.7% alcohol. It is supplied in the following oral dosage forms: NDC 0121-0772-04: 4 fl oz (118 mL) bottle NDC 0121-0772-16: 16 fl oz (473 mL) bottle NDC 0121-4772-05: 5 mL unit dose cup. Case contains 40 unit dose cups of 5 mL (NDC 0121-4772-40), packaged in 4 trays of 10 unit dose cups each. NDC 0121-1544-10: 10 mL unit dose cup. Case contains 40 unit dose cups of 10 mL (NDC 0121-1544-40), packaged in 4 trays of 10 unit dose cups each. NDC 0121-2316-15: 15 mL unit dose cup. Case contains 40 unit dose cups of 15 mL (NDC 0121-2316-40), packaged in 4 trays of 10 unit dose cups each and 50 unit dose cups of 15 mL (NDC 0121-2316-50), packaged in 5 trays of 10 unit dose cups each.
Abbreviated New Drug Application
ACETAMINOPHEN SOLUTION PAI Holdings, LLC ---------- MEDICATION GUIDE Hydrocodone Bitartrate (hye-droe-koe-done bye-tar-trate) and Acetaminophen (a-seet-a-min-oh-fen) Oral Solution CII Hydrocodone Bitartrate and Acetaminophen Oral Solution is: • A strong prescription pain medicine that contains an opioid (narcotic) that is used to manage pain severe enough to require an opioid pain medicine and for which alternative treatments are inadequate and when other pain treatments such as non-opioid pain medicines do not treat your pain well enough or you cannot tolerate them. • An opioid pain medicine that can put you at risk for overdose and death. Even if you take your dose correctly as prescribed you are at risk for opioid addiction, abuse, and misuse that can lead to death. Important information about Hydrocodone Bitartrate and Acetaminophen Oral Solution: • Get emergency help or call 911 right away if you take too much Hydrocodone Bitartrate and Acetaminophen Oral Solution (overdose). When you first start taking Hydrocodone Bitartrate and Acetaminophen Oral Solution, when your dose is changed, or if you take too much (overdose), serious or life-threatening breathing problems that can lead to death may occur. Talk to your healthcare provider about naloxone, a medicine for the emergency treatment of an opioid overdose. • Taking Hydrocodone Bitartrate and Acetaminophen Oral Solution with other opioid medicines, benzodiazepines, alcohol, or other central nervous system depressants (including street drugs) can cause severe drowsiness, decreased awareness, breathing problems, coma, and death. • Never give anyone else your Hydrocodone Bitartrate and Acetaminophen Oral Solution. They could die from taking it. Selling or giving away Hydrocodone Bitartrate and Acetaminophen Oral Solution is against the law. • Store Hydrocodone Bitartrate and Acetaminophen Oral Solution securely, out of sight and reach of children, and in a location not accessible by others, including visitors to the home. Do not take Hydrocodone Bi 전체 문서 읽기
HYDROCODONE BITARTRATE AND ACETAMINOPHEN- HYDROCODONE BITARTRATE AND ACETAMINOPHEN SOLUTION PAI HOLDINGS, LLC ---------- HYDROCODONE BITARTRATE AND ACETAMINOPHEN ORAL SOLUTION CII I07720622 REVISED: JUNE 2022 WARNING: RISK OF MEDICATION ERRORS; ADDICTION, ABUSE, AND MISUSE; RISK EVALUATION AND MITIGATION STRATEGY (REMS); LIFE- THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYTOCHROME P450 3A4 INTERACTION; HEPATOTOXICITY; AND RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS RISK OF MEDICATION ERRORS ENSURE ACCURACY WHEN PRESCRIBING, DISPENSING, AND ADMINISTERING HYDROCODONE BITARTRATE AND ACETAMINOPHEN ORAL SOLUTION. DOSING ERRORS DUE TO CONFUSION BETWEEN MG AND ML, AND OTHERHYDROCODONE BITARTRATE AND ACETAMINOPHEN ORAL SOLUTIONS OF DIFFERENT CONCENTRATIONS CAN RESULT IN ACCIDENTAL OVERDOSE AND DEATH [SEE WARNINGS, DOSAGE AND ADMINISTRATION]. ADDICTION, ABUSE, AND MISUSE HYDROCODONE BITARTRATE AND ACETAMINOPHEN ORAL SOLUTION EXPOSES PATIENTS AND OTHER USERS TO THE RISKS OF OPIOID ADDICTION, ABUSE, AND MISUSE, WHICH CAN LEAD TO OVERDOSE AND DEATH. ASSESS EACH PATIENT'S RISKPRIOR TO PRESCRIBING HYDROCODONE BITARTRATE AND ACETAMINOPHEN ORAL SOLUTION, AND MONITOR ALL PATIENTS REGULARLY FOR THE DEVELOPMENT OF THESE BEHAVIORS AND CONDITIONS [SEE WARNINGS]. OPIOID ANALGESIC RISK EVALUATION AND MITIGATION STRATEGY (REMS): TO ENSURE THAT THE BENEFITS OF OPIOID ANALGESICS OUTWEIGH THE RISKS OF ADDICTION, ABUSE, AND MISUSE, THE FOOD AND DRUG ADMINISTRATION (FDA) HAS REQUIRED A REMS FOR THESE PRODUCTS [SEE WARNINGS]. UNDER THE REQUIREMENTS OF THE REMS, DRUG COMPANIES WITH APPROVED OPIOID ANALGESIC PRODUCTS MUST MAKE REMS-COMPLIANT EDUCATION PROGRAMS AVAILABLE TO HEALTHCARE PROVIDERS. HEALTHCARE PROVIDERS ARE STRONGLY ENCOURAGED TO COMPLETE A REMS-COMPLIANT EDUCATION PROGRAM, COUNSEL PATIENTS AND/OR THEIR CAREGIVERS, WITH EVERY PRESCRIPTION, ON SAFE USE, SERIOUS RISKS, STORAGE, AND DISPOSAL OF THESE PRODUCTS, EMPHASIZE TO PATIENTS AND THEIR CAREGIVERS THE 전체 문서 읽기